Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 101

1.

Infectivity and stability of hepatitis C virus in different perfusion solutions.

Helfritz FA, Wanders V, Bojkova D, Kuklinski N, Westhaus S, Swoboda S, Minor T, Meuleman P, Paul A, Steinmann E, Ciesek S.

Transpl Infect Dis. 2019 Oct;21(5):e13135. doi: 10.1111/tid.13135. Epub 2019 Jul 12.

PMID:
31246353
2.

Animal Models for Hepatitis E virus.

Corneillie L, Banda DH, Meuleman P.

Viruses. 2019 Jun 18;11(6). pii: E564. doi: 10.3390/v11060564. Review.

3.

Hepatitis E virus prevalence in Flemish blood donors.

Vercouter AS, Van Houtte F, Verhoye L, González Fraile I, Blanco L, Compernolle V, Meuleman P.

J Viral Hepat. 2019 Oct;26(10):1218-1223. doi: 10.1111/jvh.13161. Epub 2019 Jul 24.

PMID:
31194897
4.

Hepatitis E Virus (HEV) Open Reading Frame 2 Antigen Kinetics in Human-Liver Chimeric Mice and Its Impact on HEV Diagnosis.

Sayed IM, Verhoye L, Montpellier C, Abravanel F, Izopet J, Cocquerel L, Meuleman P.

J Infect Dis. 2019 Jul 31;220(5):811-819. doi: 10.1093/infdis/jiz171.

PMID:
31001628
5.

New insights into the ORF2 capsid protein, a key player of the hepatitis E virus lifecycle.

Ankavay M, Montpellier C, Sayed IM, Saliou JM, Wychowski C, Saas L, Duvet S, Aliouat-Denis CM, Farhat R, de Masson d'Autume V, Meuleman P, Dubuisson J, Cocquerel L.

Sci Rep. 2019 Apr 18;9(1):6243. doi: 10.1038/s41598-019-42737-2.

6.

A central hydrophobic E1 region controls the pH range of hepatitis C virus membrane fusion and susceptibility to fusion inhibitors.

Banda DH, Perin PM, Brown RJP, Todt D, Solodenko W, Hoffmeyer P, Kumar Sahu K, Houghton M, Meuleman P, Müller R, Kirschning A, Pietschmann T.

J Hepatol. 2019 Jun;70(6):1082-1092. doi: 10.1016/j.jhep.2019.01.033. Epub 2019 Feb 13.

PMID:
30769006
7.

Functional Study of the C-Terminal Part of the Hepatitis C Virus E1 Ectodomain.

Moustafa RI, Haddad JG, Linna L, Hanoulle X, Descamps V, Mesalam AA, Baumert TF, Duverlie G, Meuleman P, Dubuisson J, Lavie M.

J Virol. 2018 Sep 26;92(20). pii: e00939-18. doi: 10.1128/JVI.00939-18. Print 2018 Oct 15.

8.

The natural compound silvestrol inhibits hepatitis E virus (HEV) replication in vitro and in vivo.

Todt D, Moeller N, Praditya D, Kinast V, Friesland M, Engelmann M, Verhoye L, Sayed IM, Behrendt P, Dao Thi VL, Meuleman P, Steinmann E.

Antiviral Res. 2018 Sep;157:151-158. doi: 10.1016/j.antiviral.2018.07.010. Epub 2018 Jul 20.

9.

Methylene Blue Treatment of Grafts During Cold Ischemia Time Reduces the Risk of Hepatitis C Virus Transmission.

Helfritz FA, Bojkova D, Wanders V, Kuklinski N, Westhaus S, von Horn C, Rauen U, Gallinat A, Baba HA, Skyschally A, Swoboda S, Kinast V, Steinmann E, Heusch G, Minor T, Meuleman P, Paul A, Ciesek S.

J Infect Dis. 2018 Oct 20;218(11):1711-1721. doi: 10.1093/infdis/jiy386.

PMID:
29939277
10.

Animal Models to Study Hepatitis C Virus Infection.

Burm R, Collignon L, Mesalam AA, Meuleman P.

Front Immunol. 2018 May 14;9:1032. doi: 10.3389/fimmu.2018.01032. eCollection 2018. Review.

11.

Absence of zoonotic hepatitis E virus infection in Flemish dairy cows.

Vercouter AS, Sayed IM, Lipkens Z, De Bleecker K, De Vliegher S, Colman R, Koppelman M, Supré K, Meuleman P.

Int J Food Microbiol. 2018 Sep 20;281:54-59. doi: 10.1016/j.ijfoodmicro.2018.05.009. Epub 2018 May 9.

PMID:
29852395
12.

Immunological responses following administration of a genotype 1a/1b/2/3a quadrivalent HCV VLP vaccine.

Christiansen D, Earnest-Silveira L, Chua B, Meuleman P, Boo I, Grubor-Bauk B, Jackson DC, Keck ZY, Foung SKH, Drummer HE, Gowans EJ, Torresi J.

Sci Rep. 2018 Apr 24;8(1):6483. doi: 10.1038/s41598-018-24762-9.

13.

Elucidating the differences in pathogenicity between hepatitis E virus genotypes: The quest continues.

Vercouter AS, Meuleman P.

Hepatol Commun. 2018 Feb 2;2(2):128-130. doi: 10.1002/hep4.1152. eCollection 2018 Feb. No abstract available.

14.

Development and characterization of a human monoclonal antibody targeting the N-terminal region of hepatitis C virus envelope glycoprotein E1.

Mesalam AA, Desombere I, Farhoudi A, Van Houtte F, Verhoye L, Ball J, Dubuisson J, Foung SKH, Patel AH, Persson MAA, Leroux-Roels G, Meuleman P.

Virology. 2018 Jan 15;514:30-41. doi: 10.1016/j.virol.2017.10.019. Epub 2017 Nov 10.

15.

A novel neutralizing human monoclonal antibody broadly abrogates hepatitis C virus infection in vitro and in vivo.

Desombere I, Mesalam AA, Urbanowicz RA, Van Houtte F, Verhoye L, Keck ZY, Farhoudi A, Vercauteren K, Weening KE, Baumert TF, Patel AH, Foung SKH, Ball J, Leroux-Roels G, Meuleman P.

Antiviral Res. 2017 Dec;148:53-64. doi: 10.1016/j.antiviral.2017.10.015. Epub 2017 Oct 23.

16.

Murine Tissues of Human Liver Chimeric Mice Are Not Susceptible to Hepatitis E Virus Genotypes 1 and 3.

Sayed IM, Meuleman P.

J Infect Dis. 2017 Oct 17;216(7):919-920. doi: 10.1093/infdis/jix422. No abstract available.

PMID:
28968853
17.

Hepatitis E Virus Lifecycle and Identification of 3 Forms of the ORF2 Capsid Protein.

Montpellier C, Wychowski C, Sayed IM, Meunier JC, Saliou JM, Ankavay M, Bull A, Pillez A, Abravanel F, Helle F, Brochot E, Drobecq H, Farhat R, Aliouat-Denis CM, Haddad JG, Izopet J, Meuleman P, Goffard A, Dubuisson J, Cocquerel L.

Gastroenterology. 2018 Jan;154(1):211-223.e8. doi: 10.1053/j.gastro.2017.09.020. Epub 2017 Sep 25.

PMID:
28958858
18.

Pentagalloylglucose, a highly bioavailable polyphenolic compound present in Cortex moutan, efficiently blocks hepatitis C virus entry.

Behrendt P, Perin P, Menzel N, Banda D, Pfaender S, Alves MP, Thiel V, Meuleman P, Colpitts CC, Schang LM, Vondran FWR, Anggakusuma, Manns MP, Steinmann E, Pietschmann T.

Antiviral Res. 2017 Nov;147:19-28. doi: 10.1016/j.antiviral.2017.09.006. Epub 2017 Sep 18.

PMID:
28923507
19.

Transmission of hepatitis E virus infection to human-liver chimeric FRG mice using patient plasma.

Sayed IM, Foquet L, Verhoye L, Abravanel F, Farhoudi A, Leroux-Roels G, Izopet J, Meuleman P.

Antiviral Res. 2017 May;141:150-154. doi: 10.1016/j.antiviral.2017.02.011. Epub 2017 Feb 21.

PMID:
28232247
20.

Erratum: Tuning a cellular lipid kinase activity adapts hepatitis C virus to replication in cell culture.

Harak C, Meyrath M, Romero-Brey I, Schenk C, Gondeau C, Schult P, Esser-Nobis K, Saeed M, Neddermann P, Schnitzler P, Gotthardt D, Perez-Del-Pulgar S, Neumann-Haefelin C, Thimme R, Meuleman P, Florian WR, De Francesco R, Rice CM, Bartenschlager R, Lohmann V.

Nat Microbiol. 2017 Jan 23;2:17012. doi: 10.1038/nmicrobiol.2017.12. No abstract available.

PMID:
28112725
21.

Tracking HCV protease population diversity during transmission and susceptibility of founder populations to antiviral therapy.

Khera T, Todt D, Vercauteren K, McClure CP, Verhoye L, Farhoudi A, Bhuju S, Geffers R, Baumert TF, Steinmann E, Meuleman P, Pietschmann T, Brown RJ.

Antiviral Res. 2017 Mar;139:129-137. doi: 10.1016/j.antiviral.2017.01.001. Epub 2017 Jan 3.

22.

Tuning a cellular lipid kinase activity adapts hepatitis C virus to replication in cell culture.

Harak C, Meyrath M, Romero-Brey I, Schenk C, Gondeau C, Schult P, Esser-Nobis K, Saeed M, Neddermann P, Schnitzler P, Gotthardt D, Perez-Del-Pulgar S, Neumann-Haefelin C, Thimme R, Meuleman P, Vondran FW, De Francesco R, Rice CM, Bartenschlager R, Lohmann V.

Nat Microbiol. 2016 Dec 19;2:16247. doi: 10.1038/nmicrobiol.2016.247. Erratum in: Nat Microbiol. 2017 Jan 23;2:17012.

PMID:
27991882
23.

Expanding the Host Range of Hepatitis C Virus through Viral Adaptation.

von Schaewen M, Dorner M, Hueging K, Foquet L, Gerges S, Hrebikova G, Heller B, Bitzegeio J, Doerrbecker J, Horwitz JA, Gerold G, Suerbaum S, Rice CM, Meuleman P, Pietschmann T, Ploss A.

MBio. 2016 Nov 8;7(6). pii: e01915-16. doi: 10.1128/mBio.01915-16.

24.

Successful Engraftment of Human Hepatocytes in uPA-SCID and FRG® KO Mice.

Foquet L, Wilson EM, Verhoye L, Grompe M, Leroux-Roels G, Bial J, Meuleman P.

Methods Mol Biol. 2017;1506:117-130.

PMID:
27830549
25.

Hepatitis E virus in acute liver failure: An unusual suspect?

Sayed IM, Vercouter AS, Meuleman P.

Hepatology. 2016 Dec;64(6):1837-1839. doi: 10.1002/hep.28759. Epub 2016 Sep 30. No abstract available.

PMID:
27496198
26.

Identification of a New Benzimidazole Derivative as an Antiviral against Hepatitis C Virus.

Vausselin T, Séron K, Lavie M, Mesalam AA, Lemasson M, Belouzard S, Fénéant L, Danneels A, Rouillé Y, Cocquerel L, Foquet L, Rosenberg AR, Wychowski C, Meuleman P, Melnyk P, Dubuisson J.

J Virol. 2016 Sep 12;90(19):8422-34. doi: 10.1128/JVI.00404-16. Print 2016 Oct 1.

27.

Mouse Systems to Model Hepatitis C Virus Treatment and Associated Resistance.

Mesalam AA, Vercauteren K, Meuleman P.

Viruses. 2016 Jun 22;8(6). pii: E176. doi: 10.3390/v8060176. Review.

28.

Characterization of a hepatitis C virus-like particle vaccine produced in a human hepatocyte-derived cell line.

Earnest-Silveira L, Chua B, Chin R, Christiansen D, Johnson D, Herrmann S, Ralph SA, Vercauteren K, Mesalam A, Meuleman P, Das S, Boo I, Drummer H, Bock CT, Gowans EJ, Jackson DC, Torresi J.

J Gen Virol. 2016 Aug;97(8):1865-76. doi: 10.1099/jgv.0.000493. Epub 2016 May 4.

PMID:
27147296
29.

Study of hepatitis E virus infection of genotype 1 and 3 in mice with humanised liver.

Sayed IM, Verhoye L, Cocquerel L, Abravanel F, Foquet L, Montpellier C, Debing Y, Farhoudi A, Wychowski C, Dubuisson J, Leroux-Roels G, Neyts J, Izopet J, Michiels T, Meuleman P.

Gut. 2017 May;66(5):920-929. doi: 10.1136/gutjnl-2015-311109. Epub 2016 Mar 22.

PMID:
27006186
30.

Metabolic studies of prostanozol with the uPA-SCID chimeric mouse model and human liver microsomes.

Geldof L, Lootens L, Decroix L, Botrè F, Meuleman P, Leroux-Roels G, Deventer K, Van Eenoo P.

Steroids. 2016 Mar;107:139-48. doi: 10.1016/j.steroids.2016.01.005. Epub 2016 Jan 13.

PMID:
26774429
31.

Monoclonal anti-envelope antibody AP33 protects humanized mice against a patient-derived hepatitis C virus challenge.

Desombere I, Fafi-Kremer S, Van Houtte F, Pessaux P, Farhoudi A, Heydmann L, Verhoye L, Cole S, McKeating JA, Leroux-Roels G, Baumert TF, Patel AH, Meuleman P.

Hepatology. 2016 Apr;63(4):1120-34. doi: 10.1002/hep.28428. Epub 2016 Feb 22.

PMID:
26710081
32.

In vitro and in vivo metabolism studies of dimethazine.

Geldof L, Tudela E, Lootens L, van Lysebeth J, Meuleman P, Leroux-Roels G, van Eenoo P, Deventer K.

Biomed Chromatogr. 2016 Aug;30(8):1202-9. doi: 10.1002/bmc.3668. Epub 2016 Jan 18.

PMID:
26663462
33.

HVR1-mediated antibody evasion of highly infectious in vivo adapted HCV in humanised mice.

Prentoe J, Verhoye L, Velázquez Moctezuma R, Buysschaert C, Farhoudi A, Wang R, Alter H, Meuleman P, Bukh J.

Gut. 2016 Dec;65(12):1988-1997. doi: 10.1136/gutjnl-2015-310300. Epub 2015 Nov 20.

34.

Assessment of Parasite Liver-Stage Burden in Human-Liver Chimeric Mice.

Foquet L, Meuleman P, Hermsen CC, Sauerwein R, Leroux-Roels G.

Methods Mol Biol. 2015;1325:59-68. doi: 10.1007/978-1-4939-2815-6_5.

PMID:
26450379
35.

Apolipoprotein E Mediates Evasion From Hepatitis C Virus Neutralizing Antibodies.

Fauvelle C, Felmlee DJ, Crouchet E, Lee J, Heydmann L, Lefèvre M, Magri A, Hiet MS, Fofana I, Habersetzer F, Foung SK, Milne R, Patel AH, Vercauteren K, Meuleman P, Zeisel MB, Bartenschlager R, Schuster C, Baumert TF.

Gastroenterology. 2016 Jan;150(1):206-217.e4. doi: 10.1053/j.gastro.2015.09.014. Epub 2015 Sep 25.

PMID:
26404951
36.

Targeting a host-cell entry factor barricades antiviral-resistant HCV variants from on-therapy breakthrough in human-liver mice.

Vercauteren K, Brown RJ, Mesalam AA, Doerrbecker J, Bhuju S, Geffers R, Van Den Eede N, McClure CP, Troise F, Verhoye L, Baumert T, Farhoudi A, Cortese R, Ball JK, Leroux-Roels G, Pietschmann T, Nicosia A, Meuleman P.

Gut. 2016 Dec;65(12):2029-2034. doi: 10.1136/gutjnl-2014-309045. Epub 2015 Aug 25.

PMID:
26306759
37.

Animal models for the study of HCV.

Vercauteren K, de Jong YP, Meuleman P.

Curr Opin Virol. 2015 Aug;13:67-74. doi: 10.1016/j.coviro.2015.04.009. Epub 2015 May 23. Review.

38.

Host cell mTORC1 is required for HCV RNA replication.

Stöhr S, Costa R, Sandmann L, Westhaus S, Pfaender S, Anggakusuma, Dazert E, Meuleman P, Vondran FW, Manns MP, Steinmann E, von Hahn T, Ciesek S.

Gut. 2016 Dec;65(12):2017-2028. doi: 10.1136/gutjnl-2014-308971. Epub 2015 Aug 14.

39.

Flunarizine prevents hepatitis C virus membrane fusion in a genotype-dependent manner by targeting the potential fusion peptide within E1.

Perin PM, Haid S, Brown RJ, Doerrbecker J, Schulze K, Zeilinger C, von Schaewen M, Heller B, Vercauteren K, Luxenburger E, Baktash YM, Vondran FW, Speerstra S, Awadh A, Mukhtarov F, Schang LM, Kirschning A, Müller R, Guzman CA, Kaderali L, Randall G, Meuleman P, Ploss A, Pietschmann T.

Hepatology. 2016 Jan;63(1):49-62. doi: 10.1002/hep.28111. Epub 2015 Oct 9.

40.

Polyphenols Inhibit Hepatitis C Virus Entry by a New Mechanism of Action.

Calland N, Sahuc ME, Belouzard S, Pène V, Bonnafous P, Mesalam AA, Deloison G, Descamps V, Sahpaz S, Wychowski C, Lambert O, Brodin P, Duverlie G, Meuleman P, Rosenberg AR, Dubuisson J, Rouillé Y, Séron K.

J Virol. 2015 Oct;89(19):10053-63. doi: 10.1128/JVI.01473-15. Epub 2015 Jul 22.

41.

Is hepatitis E virus an emerging problem in industrialized countries?

Sayed IM, Vercouter AS, Abdelwahab SF, Vercauteren K, Meuleman P.

Hepatology. 2015 Dec;62(6):1883-92. doi: 10.1002/hep.27990. Epub 2015 Aug 28. Review.

PMID:
26175182
42.

Clearance of persistent hepatitis C virus infection in humanized mice using a claudin-1-targeting monoclonal antibody.

Mailly L, Xiao F, Lupberger J, Wilson GK, Aubert P, Duong FHT, Calabrese D, Leboeuf C, Fofana I, Thumann C, Bandiera S, Lütgehetmann M, Volz T, Davis C, Harris HJ, Mee CJ, Girardi E, Chane-Woon-Ming B, Ericsson M, Fletcher N, Bartenschlager R, Pessaux P, Vercauteren K, Meuleman P, Villa P, Kaderali L, Pfeffer S, Heim MH, Neunlist M, Zeisel MB, Dandri M, McKeating JA, Robinet E, Baumert TF.

Nat Biotechnol. 2015 May;33(5):549-554. doi: 10.1038/nbt.3179. Epub 2015 Mar 23.

43.

Anti-CD81 but not anti-SR-BI blocks Plasmodium falciparum liver infection in a humanized mouse model.

Foquet L, Hermsen CC, Verhoye L, van Gemert GJ, Cortese R, Nicosia A, Sauerwein RW, Leroux-Roels G, Meuleman P.

J Antimicrob Chemother. 2015;70(6):1784-7. doi: 10.1093/jac/dkv019. Epub 2015 Feb 4.

PMID:
25656410
44.

Generation and characterization of small single domain antibodies inhibiting human tumor necrosis factor receptor 1.

Steeland S, Puimège L, Vandenbroucke RE, Van Hauwermeiren F, Haustraete J, Devoogdt N, Hulpiau P, Leroux-Roels G, Laukens D, Meuleman P, De Vos M, Libert C.

J Biol Chem. 2015 Feb 13;290(7):4022-37. doi: 10.1074/jbc.M114.617787. Epub 2014 Dec 23.

45.

Impact of lipids and lipoproteins on hepatitis C virus infection and virus neutralization.

Vercauteren K, Mesalam AA, Leroux-Roels G, Meuleman P.

World J Gastroenterol. 2014 Nov 21;20(43):15975-91. doi: 10.3748/wjg.v20.i43.15975. Review.

46.

HCV animal models and liver disease.

Vercauteren K, de Jong YP, Meuleman P.

J Hepatol. 2014 Nov;61(1 Suppl):S26-33. doi: 10.1016/j.jhep.2014.07.013. Epub 2014 Nov 3. Review.

47.

A genetically attenuated malaria vaccine candidate based on P. falciparum b9/slarp gene-deficient sporozoites.

van Schaijk BC, Ploemen IH, Annoura T, Vos MW, Foquet L, van Gemert GJ, Chevalley-Maurel S, van de Vegte-Bolmer M, Sajid M, Franetich JF, Lorthiois A, Leroux-Roels G, Meuleman P, Hermsen CC, Mazier D, Hoffman SL, Janse CJ, Khan SM, Sauerwein RW.

Elife. 2014 Nov 19;3. doi: 10.7554/eLife.03582.

48.

Successful anti-scavenger receptor class B type I (SR-BI) monoclonal antibody therapy in humanized mice after challenge with HCV variants with in vitro resistance to SR-BI-targeting agents.

Vercauteren K, Van Den Eede N, Mesalam AA, Belouzard S, Catanese MT, Bankwitz D, Wong-Staal F, Cortese R, Dubuisson J, Rice CM, Pietschmann T, Leroux-Roels G, Nicosia A, Meuleman P.

Hepatology. 2014 Nov;60(5):1508-18. doi: 10.1002/hep.27196. Epub 2014 Jul 30.

49.

Sporozoite immunization of human volunteers under chemoprophylaxis induces functional antibodies against pre-erythrocytic stages of Plasmodium falciparum.

Behet MC, Foquet L, van Gemert GJ, Bijker EM, Meuleman P, Leroux-Roels G, Hermsen CC, Scholzen A, Sauerwein RW.

Malar J. 2014 Apr 5;13:136. doi: 10.1186/1475-2875-13-136.

50.

Combined adenovirus vector and hepatitis C virus envelope protein prime-boost regimen elicits T cell and neutralizing antibody immune responses.

Chmielewska AM, Naddeo M, Capone S, Ammendola V, Hu K, Meredith L, Verhoye L, Rychlowska M, Rappuoli R, Ulmer JB, Colloca S, Nicosia A, Cortese R, Leroux-Roels G, Balfe P, Bienkowska-Szewczyk K, Meuleman P, McKeating JA, Folgori A.

J Virol. 2014 May;88(10):5502-10. doi: 10.1128/JVI.03574-13. Epub 2014 Mar 5.

Supplemental Content

Loading ...
Support Center